Michael Bruno

Cooley advised Vividly, the top trade promotion management platform for consumer packaged goods brands, on its $30 million Series B financing. Centana Growth Partners led the funding round. Stephane Levy, Scott Rudin and Michael Bruno led the Cooley team advising Vividly.

Cooley advised Spring Health, the top global mental health solution for employers and health plans, on its $100 million Series E financing with a valuation of $3.3 billion.

Cooley advised Tomorrow Health on its $60 million Series B financing. Tomorrow Health is the developer of a data-driven medical equipment sourcing platform intended to streamline ordering and access to home medical equipment supplies for patients and their families. Partner Sacha Ross led the Cooley team.

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Cooley advised LAVA Therapeutics on its $106.9 million initial public offering of 7,125,712 shares of common stock, which includes the underwriters’ partial exercise of their option to purchase additional shares. LAVA Therapeutics, whose securities now trade on the Nasdaq Global Select Market  under the symbol LVTX, is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T-cell-mediated immunity against tumor cells. Partners Christian Plaza, Div Gupta and Josh Kaufman led the Cooley team.